Twenty-five years ago, the cytotoxic drug irinotecan (IRT) was first approved in Japan for the
treatment of cancer. For more than two decades, the IRT prodrug has largely contributed to …

CA4 is a potent microtubule polymerization inhibitor and vascular disrupting agent.
However, the in vivo efficiency of CA4 is limited owing to its poor pharmacokinetics resulting …

Pancreatic cancer (PC) is one kind of the most lethal malignancies worldwide, owing to its
insidious symptoms, early metastases, and negative responses to current therapies. With an …

Cancer is still one of the major problems threatening human health and the therapeutical
efficacies of available treatment choices are often rather low. Due to their favorable …

Peptide-drug conjugates (PDCs) are the new hope for targeted therapy after antibody-drug
conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced …

Pancreatic cancer is fast becoming a global menace and it is projected to be the second
leading cause of cancer-related death by 2030. Pancreatic adenocarcinomas, which …

Specifically addressing cell surface molecules on cancer cells facilitates targeted cancer
therapies that offer the potential to selectively destroy malignant cells, while sparing healthy …

The epidermal growth factor–epidermal growth factor receptor (EGF-EGFR) pathway has
become the main focus of selective chemotherapeutic intervention. As a result, two classes …

Pancreatic cancer is a devastating disease with very poor prognosis. Currently, surgery
followed by adjuvant chemotherapy represents the only curative option which, unfortunately …

Cancers of the gastrointestinal tract constitute one of the most common cancer types
worldwide and a∼ 58% increase in the global number of cases has been estimated by …